Table 3.
Nomogram | ELR | LR | MR | HR | Total | Total P value | ELR-LR | ELR-MR | ELR-HR | LR-MR | LR-HR | MR-HR |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0-50 | 51-100 | 101-150 | >150 | P value | P value | P value | P value | P value | P value | |||
Training dataset | ||||||||||||
Without CLNM | 90 (87.4%) | 128 (70.3%) | 66 (37.9%) | 27 (17.1%) | 311 | |||||||
With CLNM | 13 (12.6%) | 54 (29.7%) | 108 (62.1%) | 131 (82.9%) | 306 | <0.001 | 0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
Total | 103 | 182 | 174 | 158 | 617 | |||||||
Validation dataset | ||||||||||||
Without CLNM | 44 (88.0%) | 54 (68.4%) | 29 (39.7%) | 11 (16.4%) | 138 | |||||||
With CLNM | 6 (12.0%) | 25 (31.6%) | 44 (60.3%) | 56 (83.6%) | 131 | <0.001 | 0.011 | <0.001 | <0.001 | <0.001 | <0.001 | 0.002 |
Total | 50 | 79 | 73 | 67 | 269 |
PTC, papillary thyroid carcinoma; CLNM, central lymph node metastasis; ELR, extreme low risk; LR, low risk; MR, moderated risk; HR, high risk.